Skip to content

Randomized control trial of Qingre Lidan tablet on postoperative blood routine and liver function in patients with obstructive jaundice

Randomized control trial of Qingre Lidan tablet on postoperative blood routine and liver function in patients with obstructive jaundice

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062837
Enrollment
Unknown
Registered
2022-08-20
Start date
2022-09-03
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Jaundice

Interventions

Experimental group:Ursodeoxycholic acid+Qingre Lidan tablets

Sponsors

Tianjin Nankai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Those who meet the diagnostic criteria of obstructive jaundice, have imaging diagnosis of common bile duct stones and meet the surgical indications, and plan to undergo biliary surgery; 2. Aged 18-70 years; 3. Patients without primary heart, liver, lung and kidney diseases; 4. It meets the diagnostic criteria of TCM syndrome type of Qingre Lidan prescription (Yinchenhao Decoction+Dachengqi Decoction); 5. Patients voluntarily joined this clinical study and signed informed consent, with good compliance.

Exclusion criteria

Exclusion criteria: 1. Previous heart disease (cardiac insufficiency); 2. Patients with immune diseases, liver and kidney insufficiency, blood diseases, diabetes and poisoning; 3. Patients with malignant or unexplained obstructive jaundice; 4. Other circumstances that the researcher determines are not suitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
Routine blood test;Liver function;

Countries

China

Contacts

Public ContactZehan Liu

Tianjin Medical University

liuzehan@tmu.edu.cn+86 1761297007

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026